期刊文献+

卡培他滨单药治疗局部晚期乳腺癌24例疗效观察 被引量:2

下载PDF
导出
摘要 目的:评价卡培他滨单药治疗局部晚期乳腺癌的疗效及毒副作用。方法:24例局部晚期乳腺癌患者给予卡培他滨2500mg·m^(-2)·d^(-1),连用2周,每3周为1个周期,常规治疗6~8周期,有严重毒副作用者需停药或减量。结果:肿瘤完全缓解(CR)2例,部分缓解(PR)9例,稳定(SD)10例,进展(PD)3例。总有效率为45.8%主要不良反应为手足综合征,经调整剂量可缓解。结论:卡培他滨单药治疗局部晚期乳腺癌疗效确切,安全性较高,可作为局部晚期乳腺癌的一线治疗药物。
出处 《中国药师》 CAS 2009年第1期103-104,共2页 China Pharmacist
  • 相关文献

参考文献5

  • 1Ishikawa T,Utoh M, Sauada N,et al. Tumor selective delivery of 5-fluorouracil by capecitabine,a new oral fluoropyrimidine carbamale,in human cancer xenografts [ J ]. Biochem Pharmoco1,2003,55 ( 7 ) : 1091-1097.
  • 2Rossi D, Alessandroni P, Catalano V ,et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer [ J ]. Clin Breast Cancer, 2007,7( 11 ) :857-860.
  • 3Seidman AD, O'Shaughnessy J, Misset JL. Single-agent capecit-abine: a reference treatment for taxane-pretreated metastatic breast cancer [ J ]. Oncologist, 2002,7 ( Suppl 6) : 20-28.
  • 4贾宝辉,史成章.新型选择性肿瘤化疗药物──卡培他滨[J].国外医学(药学分册),2002,29(5):282-286. 被引量:10
  • 5Maroun J A. Capecitabine in the management of colorectal cancer[ J ]. Exp Rev Anticancer Ther,2001,32( 1 ) :327-333.

二级参考文献27

  • 1Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma[J]. JNatl CancerInst, 1996, 88(16):1110- 1117.
  • 2Tsukamoto Y, Kato Y, Ura M, et al. Investigation of 5-FU disposition after oral administration of capecitabine, a tripleprodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue betwcen human and xenograft model[J]. Biopharm Drug Dispos, 2001, 22(1): 1-14.
  • 3Ishikawa T, Utoh M, Sawada N, et al. Tumor selective dehvery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [J].Biochem Pharmacol, 1998, 55(7): 1091-1097.
  • 4Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts[J]. Cancer Res, 1998, 58(3) :685-690.
  • 5Ishikawa T, Fukase Y, Yamamoto T, et al. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine) [J]. Biol Pharm Bull, 1998, 21(7) :713- 717.
  • 6Schuller J, Gassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J]. Cancer Chemother Pharmacol, 2000, 45(4) :291-297.
  • 7Reigner B, Verweij J, Dirix L, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients[J]. Clin Cancer Res, 1998, 4(4) :941-948.
  • 8Reigner B, Clive S, Cassidy J, et al. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients [J]. Cancer Chemother Pharmacol , 1999,43(4) :309-315.
  • 9Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites[J]. Clin Cancer Res, 1999, 5(7): 1696-1702.
  • 10Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients [J]. Cancer Chemother Pharmacol, 2002, 49(3) :225-234.

共引文献9

同被引文献9

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部